KontrolFreek has been acquired by SteelSeries
The shareholders of KontrolFreek, LLC (KF) have sold the company to SteelSeries.
KontrolFreek designs, markets and manufactures innovative gaming accessories for players of all skill levels, including eSports professionals. The company’s performance thumbsticks and grips are engineered to enhance the gaming experience by improving player comfort and accuracy while reducing thumb fatigue. KF’s products are sold directly to consumers through KontrolFreek.com, as well as through premier brick-and-mortar and online retailers, which include Amazon, GameStop and Best Buy, among others. KF also partners with video game publishers to offer licensed products and bundles.
SteelSeries is a leading Danish manufacturer of gaming peripherals and accessories, including headsets, keyboards, mice and gaming surfaces.
Oaklins’ team in Los Angeles served as the exclusive sell-side advisor to KontrolFreek in this transaction.
Talk to the deal team
Gary S. Rabishaw
Oaklins Intrepid
Andrew Colmar
Oaklins Intrepid
Related deals
OBI Group has acquired the OBI and individual DIG stores from Migros
As part of a strategic review, Migros has decided to divest its DIY business, which included several “Do It + Garden” and “OBI” locations. Migros had operated the Swiss OBI stores as a franchisee. In OBI Group Holding, Migros has found the ideal partner to ensure continuity for both its customers and employees.
Learn moreDen Berk Délice accelerates growth through strategic partnership
Den Berk Délice, a leading Belgian grower of specialty tomatoes, has entered a strategic partnership with Egeria, an independent investment firm, to realize its next growth phase.
Learn moreXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Learn more